[Skip to Navigation]
Sign In
Views 622
Citations 0
Comment & Response
June 10, 2021

Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker

Author Affiliations
  • 1The Medical Department, 3D Medicines Inc, Shanghai, China
  • 2Department of Oncology, Fifth Medical Center of Chinese PLA General Hospital/Medical School of Chinese PLA, Beijing, China
JAMA Oncol. 2021;7(8):1244-1245. doi:10.1001/jamaoncol.2021.1867

To the Editor We read with great interest the article by Valero et al1 that described response rates, with respect to tumors with 10 or more mutations per megabase, in a cohort of 1678 patients treated with immune checkpoint inhibitors (ICIs). Including this study, the same research group reported 3 related studies recently. The other 2 studies, by Samstein et al2 and Valero et al,3 reported the predictive value of tumor mutation burden (TMB) on immunotherapy with the top 20 percentile (20%) as the cutoff and the association of TMB with survival with or without the immunotherapy context in patients with cancer, respectively. Although most of the patients with cancer receiving immunotherapy in these studies overlapped and some of the results were also duplicated, these 3 studies reported real-world data on immunotherapy, provided important clues for the clinical application of TMB as a biomarker, and guided possible ICI trial design. For this research, we have 2 comments.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words